P/E của cổ phiếu INCY là bao nhiêu?

Incyte Corporation (INCY) hiện giao dịch ở mức P/E 15.46 lần.

ROE của cổ phiếu INCY là bao nhiêu?

Incyte Corporation có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 25.41%.

Tỷ suất cổ tức của INCY là bao nhiêu?

Incyte Corporation có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của INCY là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của INCY ở mức 100/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu INCY không?

Điểm AI Timing của INCY là 87/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu INCY thuộc ngành nào?

Incyte Corporation được xếp vào ngành Healthcare >> Biotechnology trên sàn NASDAQ

Cổ phiếu INCY (NASDAQ) | INCYTE CORPORATION

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-06-30)

INCY AI Analysis Summary

Our AI summary for INCY: Incyte Corporation (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 15.46, ROE of 25.41%, a dividend yield of 0.00%. Its financial Quality Score stands at 100/100 — fundamentals stronger than most of the market. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

INCY

Incyte Corporation

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 119.52

-3.47 (-2.82%) Day Change

Watchlist Portfolio Compare Chart

15.46

P/E

0.00

D/E

25.4%

ROE

20.5%

ROA

0.00%

Div Yield

0.01

PEG

INCYTE CORPORATION
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 119.52 Price -3.47 (-2.82%) Day Change	NEWS SCORE: N/A

INCY Chất lượng tổng thể của cố phiếu Xuất sắc ( Chất lượng = 100) và Thời điểm mua ...(Sign In to See)...

Loading chart...

100 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Excellent

Reason: Sức khỏe tài chính của công ty Xuất sắc từ hầu hết các chỉ số chất lượng

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Tốt , ...

Yếu tố Chất lượng

58%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.12 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	418
Magic Formula Rank by ROE	418
Magic Formula Rank by ROIC	394
Price	119.52
PBV / Sector	3.93 / 5.20
Earning Per Share	7.73

PE / Sector	15.46 / 19.97
PEG or PE/Growth / Sector	0.01 / 1.22 GREAT
Average 1M Daily Value	219.55 M GREAT
Average 1W Daily Value	392.72 M GREAT

Yếu tố Kỹ thuật

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

52%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

75%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	27.71 / 98.71 GREAT
NPM Average (%) / Sector	15.94 / -1,721.76 GREAT
NPM Change Average (%) / Sector	782.74 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	20.48 / 27.02 GOOD
ROA Average (%) / Sector	10.84 / -368.17
ROA Change Average (%) / Sector	738.85 / 5,404.12 GREAT
ROE (%) / Sector	25.41 / 3.47 GOOD
ROE Average (%) / Sector	14.11 / 6.51
ROE Change Average (%) / Sector	622.50 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Chi tiết đăng ký

Analyze Date	2026-08-01 08:00:01
Symbol	INCY
Name	INCYTE CORPORATION
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	202.70 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	24,929.80 / 9,903.94

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803

Phone: 302 498 6700

Website: https://www.incyte.com

Employees: 2,844

Sector: Healthcare >> Biotechnology

Description: Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.